GLO 1 and PKCλ Regulate ALDH1-positive Breast Cancer Stem Cell Survival.


Journal

Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988

Informations de publication

Date de publication:
Dec 2021
Historique:
received: 11 09 2021
revised: 30 09 2021
accepted: 01 10 2021
entrez: 1 12 2021
pubmed: 2 12 2021
medline: 15 12 2021
Statut: ppublish

Résumé

We examined the inhibitory effects of both glyoxalase 1 (GLO 1) and protein kinase C (PKC)λ in aldehyde dehydrogenase 1 (ALDH1)-positive breast cancer stem cells (CSCs). Breast cancer genomics datasets (TCGA, n=593; METABRIC, n=1904) were downloaded and statistically analyzed. The effects of GLO 1 and PKCλ on trypan blue staining and tumor-sphere formation by ALDH1 GLO 1 GLO 1 and PKCλ are important for the survival of ALDH1-positive breast CSCs, and may represent potential therapeutic targets for the treatment of ALDH1-positive breast CSCs.

Sections du résumé

BACKGROUND/AIM OBJECTIVE
We examined the inhibitory effects of both glyoxalase 1 (GLO 1) and protein kinase C (PKC)λ in aldehyde dehydrogenase 1 (ALDH1)-positive breast cancer stem cells (CSCs).
MATERIALS AND METHODS METHODS
Breast cancer genomics datasets (TCGA, n=593; METABRIC, n=1904) were downloaded and statistically analyzed. The effects of GLO 1 and PKCλ on trypan blue staining and tumor-sphere formation by ALDH1
RESULTS RESULTS
GLO 1
CONCLUSION CONCLUSIONS
GLO 1 and PKCλ are important for the survival of ALDH1-positive breast CSCs, and may represent potential therapeutic targets for the treatment of ALDH1-positive breast CSCs.

Identifiants

pubmed: 34848450
pii: 41/12/5959
doi: 10.21873/anticanres.15415
doi:

Substances chimiques

Biomarkers, Tumor 0
Isoenzymes 0
Aldehyde Dehydrogenase 1 Family EC 1.2.1
Protein Kinase C EC 2.7.11.13
protein kinase C lambda EC 2.7.11.13
GLO1 protein, human EC 4.4.1.5
Lactoylglutathione Lyase EC 4.4.1.5

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

5959-5971

Informations de copyright

Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Auteurs

Hitomi Motomura (H)

Department of Medicinal and Life Sciences, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba, Japan.

Shoma Tamori (S)

Department of Medicinal and Life Sciences, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba, Japan.

Masa-Aki Yatani (MA)

Department of Medicinal and Life Sciences, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba, Japan.

Ayano Namiki (A)

Department of Medicinal and Life Sciences, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba, Japan.

Chotaro Onaga (C)

Department of Medicinal and Life Sciences, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba, Japan.

Ayaka Ozaki (A)

Department of Medicinal and Life Sciences, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba, Japan.

Ryoko Takasawa (R)

Department of Pharmacy, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba, Japan.

Yasunari Mano (Y)

Department of Pharmacy, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba, Japan.

Tsugumichi Sato (T)

Department of Pharmacy, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba, Japan.

Yasushi Hara (Y)

Research Institute for Biomedical Sciences, Tokyo University of Science, Chiba, Japan.

Keiko Sato (K)

Department of Information Sciences, Faculty of Sciences and Technology, Tokyo University of Science, Chiba, Japan.

Yuyun Xiong (Y)

Department of Medicinal and Life Sciences, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba, Japan.

Yohsuke Harada (Y)

Department of Medicinal and Life Sciences, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba, Japan.

Takehisa Hanawa (T)

Department of Pharmacy, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba, Japan.

Sei-Ichi Tanuma (SI)

Department of Genomic Medicinal Science, Research Institute for Science and Technology, Organization for Research Advancement, Tokyo University of Science, Chiba, Japan.

Kazunori Sasaki (K)

Department of Cancer Biology, Institute for Diseases of Old Age, Juntendo University School of Medicine, Tokyo, Japan.

Shigeo Ohno (S)

Department of Cancer Biology, Institute for Diseases of Old Age, Juntendo University School of Medicine, Tokyo, Japan.

Kazunori Akimoto (K)

Department of Medicinal and Life Sciences, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba, Japan; akimoto@rs.tus.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH